Susquehanna Portfolio Strategies’s Nurix Therapeutics NRIX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Buy	107,663 +21,240	+25%	+$352K	0.02%	537
2025 Q4	$1.64M	Buy	86,423 +71,421	+476%	+$1.03M	0.03%	541
2025 Q3	$139K	Sell	15,002 -55,668	-79%	-$578K	﹤0.01%	1002
2025 Q2	$805K	Buy	70,670 +60,120	+570%	+$650K	0.02%	554
2025 Q1	$125K	Buy	+10,550	New	+$176K	0.05%	141
2024 Q4	–	Sell	-154,044	Closed	-$3.46M	–	230
2024 Q3	$3.46M	Sell	154,044 -1,940	-1%	-$43.9K	0.24%	99
2024 Q2	$3.26M	Sell	155,984 -2,183	-1%	-$34K	0.13%	159
2024 Q1	$2.33M	Hold	158,167	–	–	0.05%	308
2023 Q4	$1.63M	Buy	+158,167	New	+$1.08M	0.03%	482

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Susquehanna Portfolio Strategies's NRIX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies increased its Nurix Therapeutics (NRIX) stake by 25% in Q1 2026, buying an estimated $352K and bringing the position to 107,663 shares worth $1.67M. The position accounts for 0.02% of the portfolio, ranked #537.

Susquehanna Portfolio Strategies first reported a position in NRIX in Q4 2023 and has held it in 9 quarters since. The position peaked at $3.46M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Susquehanna Portfolio Strategies held 107,663 shares of Nurix Therapeutics worth $1.67M as of Q1 2026.
Susquehanna Portfolio Strategies bought 21,240 Nurix Therapeutics shares in Q1 2026, an estimated $352K.
Nurix Therapeutics made up 0.02% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #537 holding.
Susquehanna Portfolio Strategies first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 9 quarters since.
Susquehanna Portfolio Strategies's Nurix Therapeutics position peaked at $3.46M in Q3 2024.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.